ABSTRACT
Expert panel recommends broader reviews of research involving pathogens or toxins that could have "dual use".
Subject(s)
Biomedical Research , Biosecurity , Containment of Biohazards , United States , Bacteria/genetics , Bacteria/pathogenicity , Viruses/genetics , Viruses/pathogenicity , Gain of Function Mutation , Humans , AnimalsABSTRACT
Two viruses plus a child's genetic background may explain a recent surge in the United Kingdom.
Subject(s)
Dependovirus , HLA Antigens , Hepatitis, Viral, Human , Child , Dependovirus/classification , Dependovirus/isolation & purification , HLA Antigens/genetics , Hepatitis, Viral, Human/epidemiology , Hepatitis, Viral, Human/genetics , Hepatitis, Viral, Human/virology , Humans , United Kingdom/epidemiologySubject(s)
Centers for Disease Control and Prevention, U.S. , Leadership , HIV , Humans , Research Personnel , United StatesABSTRACT
A review. In a notable display of urgency, researchers are already developing more than 100 treatments and vaccines to stem the COVID-19 pandemic. But onlookers worry the sprawling effort could waste time and resources on duplicated studies and weak candidates. So, last week, the National Institutes of Health (NIH) and 16 drug companies announced an effort to impose some order. In one key activity, the Accelerating COVID-19 Therapeutic Interventions and Vaccines initiative will inventory drug and vaccine candidates and decide which should get priority for U.S. funding and rigorous testing in humans. The top-rated compounds will get preferred access to NIH′s 1.8 billion pot of COVID-19 research money, as well as to a dozen or more NIH clin. trial networks originally set up for other diseases.
Subject(s)
Betacoronavirus , Chromosomes, Human, Pair 3/genetics , Coronavirus Infections/genetics , Host-Pathogen Interactions/genetics , Pneumonia, Viral/genetics , ABO Blood-Group System/genetics , COVID-19 , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/genetics , Genetic Variation , Humans , Pandemics , Receptor, Interferon alpha-beta/genetics , Receptors, CCR2/genetics , Risk Factors , SARS-CoV-2ABSTRACT
The article informs that how the coronavirus virus attacks cells around the body. It mentions that the virus lands in the lungs by binding to angiotensin converting enzyme 2 (ACE2) receptors on the cell surface with infection promoting blood clots, heart attacks, and cardiac infammation. It also mentions that some patients lose their sense of smell.
ABSTRACT
Many websites track the devastating spread of disease and death caused by the now-pandemic coronavirus, from the World Health Organization’s (WHO’s) global map to The New York Times’s tally of U.S. cases at the county level. But one of the earliest, an online dashboard run by Johns Hopkins University, has become the go-to place for the latest data on coronavirus disease 2019 (COVID-19). With its black world map strewn with red circles and global, country, and state counts of cases, deaths, and recoveries, the Coronavirus COVID-19 Global Cases tracker sticks to the basics—no fancy graphs. Yet the site, which gets more than 1 billion hits a day, has become the most authoritative source for COVID-19 case data. It is used by news organizations and government agencies around the world. Its dashboard has been copied by states and countries. It has been spotted on a wall in a photo of the U.S. Department of Health and Human Services’s coronavirus war room.
ABSTRACT
COVID-19, caused by the new pandemic coronavirus, is strangely—and tragically—selective. Only some infected people get sick, and although most of the critically ill are elderly or have complicating problems such as heart disease, some killed by the disease are previously healthy and even relatively young. Researchers are now gearing up to scour the patients’ genomes for DNA variations that explain this mystery. The findings could be used to identify those most at risk of serious illness and those who might be protected, and they might also guide the search for new treatments.
ABSTRACT
Infectious disease experts across the United States are calling for tougher enforcement of social distancing measures to slow the spread of the coronavirus behind the COVID-19 pandemic, including a nationwide closure of schools and nonessential businesses. Such a move would go beyond the spotty closures now in place in some states and major cities.
ABSTRACT
More than 100 treatments and vaccines are in development to stem the COVID-19 pandemic, and some onlookers have worried that this sprawling and potentially duplicative effort is wasting time and resources. Hoping to bring order to the chaos, the National Institutes of Health (NIH) and major drug companies today announced a plan to stage carefully designed clinical trials of the drugs and vaccines they have decided are the highest priorities for testing and development. The public-private partnership involves NIH, other U.S. government agencies, 16 pharma companies and biotechs, and the nonprofit Foundation for the National Institutes of Health (FNIH). It aims to develop “an international strategy” for COVID-19 research, a press release states. However, NIH Director Francis Collins told reporters during a press call today that “it is primarily a U.S.-focused effort.”